UNC Health Provider Ushers in First FDA-Approved Medication for Eosinophilic Esophagitis
Retrieved on:
Thursday, December 22, 2022
Research, General Health, Pharmaceutical, Other Education, Continuing, University, Education, Clinical Trials, Science, FDA, Other Science, Health, The New England Journal of Medicine, Eosinophilic esophagitis, Esophagus, Immunology, Clinical trial, Plasma protein binding, A. Lee Dellon, Communication, Stomach, American College, UNC School of Medicine, Polyp (medicine), Dysphagia, Skin, Dupilumab, Enzyme inhibitor, Inflammation, Multimedia, Food, American College of Allergy, Asthma and Immunology, Irritation, Eosinophil, Patient, Asthma, Infection, Physician, Parasitism, Swelling, FDA, EOE, Regeneron Pharmaceuticals, Sinusitis, Degenerative disease, Colon, Endoscopy, Diagnosis, MPH, Dermatitis, Annals of Allergy, Asthma & Immunology, Biopsy, Electric battery, Pharmaceutical industry, Medical imaging, MD, Allergy, Medicine
Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.
Key Points:
- Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.
- View the full release here: https://www.businesswire.com/news/home/20221222005534/en/
Evan Dellon, MD, MPH, professor of medicine at the UNC School of Medicine and director of the Center for Esophageal Diseases and Swallowing. - There is one approved treatment for EoE in several other countries, but it is not available for use in the United States.
- Dellon believes that initially most doctors will prescribe the therapy for their more severe patients who weren’t responding to prior therapies.